Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05270525 · ClinicalTrials.gov registry record · Phase 2
Effect of Ensifentrine on Sputum Markers of Inflammation in COPD
A Phase 2 study of COPD, sponsored by Verona Pharma.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
- 3
- Study locations
NCT05270525: Recruiting Phase 2 study of COPD, sponsored by Verona Pharma.
NCT05270525 is a Phase 2 study of COPD that is actively recruiting participants, run by Verona Pharma. The registered enrollment target is 56 participants, below the 2,418-participant average among 85 other COPD trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05270525, a Phase 2 study of COPD, is actively recruiting participants, sponsored by Verona Pharma.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a randomized, double-blind, placebo-controlled, two-period cross-over study of nebulized ensifentrine (3 mg) or placebo administered BID for two 8-week Treatment Periods. All participants with receive both ensifentrine and placebo during participation. There are 7 in-clinic visits over a total duration of up to 24 weeks participation.
Primary Outcome
To measure the effect of nebulized ensifentrine on sputum absolute neutrophil count after twice daily dosing.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ensifentrine
Study Locations (3)
Alabama
- University of Alabama at Birmingham - Birmingham
Michigan
- University of Michigan - Ann Arbor
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2022-05-27 |
| Est. Completion | 2027-06 |
| Phase | Phase 2 |
What NCT05270525 shows while recruiting
NCT05270525 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 2,418-participant average among 85 other COPD trials with a reported enrollment target (98% lower).
The record links to 1 condition, with COPD appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05270525 reports a single indexed study location in Alabama, Michigan, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05270525 about?
NCT05270525 is a clinical study titled "Effect of Ensifentrine on Sputum Markers of Inflammation in COPD". This is a randomized, double-blind, placebo-controlled, two-period cross-over study of nebulized ensifentrine (3 mg) or placebo administered BID for two 8-week Treatment Periods. All participants with receive both ensifentrine and placebo during participation. There are 7 in-clinic visits over a tot...
What is the current status of trial NCT05270525?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2022-05-27. Estimated completion is 2027-06.
What conditions does trial NCT05270525 study?
This clinical trial studies the following conditions: COPD.
What interventions are being tested in trial NCT05270525?
The interventions under investigation include: Placebo (DRUG), Ensifentrine (DRUG).
Who is sponsoring clinical trial NCT05270525?
This trial is sponsored by Verona Pharma, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05270525 being conducted?
This trial has 3 study locations across Alabama, Michigan, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COPD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05270525's enrollment target sits among peer trials
56 50th of 85 higher than 36 of 85 other COPD trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COPD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pulmonary Hypertension SOLAR
RECRUITING · Phase 2
-
A Study to Evaluate Solrikitug in Participants With COPD (ZION)
RECRUITING · Phase 2
-
MagniXene MRI Use in Patients With Asthma and COPD to Assess Regional Lung Function by Delineating Ventilation Defects
COMPLETED · Phase 2
-
Study to Assess the Safety and Tolerability of Incremental Doses of QAB149 in Adults With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 2
-
A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 2
-
Impact of Positive Airway Pressure Therapy on Clinical Outcomes in Older Veterans With Chronic Obstructive Pulmonary Disease and Comorbid Obstructive Sleep Apnea (Overlap Syndrome)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI